{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:31:54Z","timestamp":1790476314034,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,25]]},"DOI":"10.7759\/cureus.105842","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T16:00:27Z","timestamp":1774454427000},"source":"Crossref","is-referenced-by-count":1,"title":["Gastrointestinal Toxicities of Targeted Cancer Therapies: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Eunice K","family":"Omeludike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uchechukwu  N","family":"Oguama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nneoma","family":"Ubah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherechi O","family":"Nwabueze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nzubechukwu","family":"Okeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Aregbesola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesoma A","family":"Igbokwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher","family":"Gujral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridwan A","family":"Lawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yetunde F","family":"Akande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70006-3","article-title":"Guidance on the management of diarrhoea during cancer chemotherapy","volume":"15","author":"Andreyev J","year":"2014","unstructured":"Andreyev J, Ross P, Donnellan C, et al.. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014, 15:447-60. 10.1016\/S1470-2045(14)70006-3","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy145","article-title":"Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines","volume":"29","author":"Bossi P","year":"2018","unstructured":"Bossi P, Antonuzzo A, Cherny NI, et al.. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018, 29:iv126-42. 10.1093\/annonc\/mdy145","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.132","article-title":"Recommended guidelines for the treatment of cancer treatment-induced diarrhea","volume":"22","author":"Benson AB 3rd","year":"2004","unstructured":"Benson AB 3rd, Ajani JA, Catalano RB, et al.. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004, 22:2918-26. 10.1200\/JCO.2004.04.132","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.11.008","article-title":"Targeted therapy-induced diarrhea: a review of the literature","volume":"90","author":"Pessi MA","year":"2014","unstructured":"Pessi MA, Zilembo N, Haspinger ER, Molino L, Di Cosimo S, Garassino M, Ripamonti CI. Targeted therapy-induced diarrhea: a review of the literature. Crit Rev Oncol Hematol. 2014, 90:165-79. 10.1016\/j.critrevonc.2013.11.008","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3747\/co.21.2241","article-title":"Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors","volume":"21","author":"Hirsh V","year":"2014","unstructured":"Hirsh V, Blais N, Burkes R, Verma S, Croitoru K. Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. Curr Oncol. 2014, 21:329-36. 10.3747\/co.21.2241","journal-title":"Curr Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/1534735420928493","article-title":"Diarrhea induced by small-molecule tyrosine kinase inhibitors compared with chemotherapy: potential role of the microbiome","volume":"19","author":"Secombe KR","year":"2020","unstructured":"Secombe KR, Van Sebille YZ, Mayo BJ, Coller JK, Gibson RJ, Bowen JM. Diarrhea induced by small-molecule tyrosine kinase inhibitors compared with chemotherapy: potential role of the microbiome. Integr Cancer Ther. 2020, 19:1534735420928493. 10.1177\/1534735420928493","journal-title":"Integr Cancer Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.111","article-title":"Secretory diarrhoea: mechanisms and emerging therapies","volume":"12","author":"Thiagarajah JR","year":"2015","unstructured":"Thiagarajah JR, Donowitz M, Verkman AS. Secretory diarrhoea: mechanisms and emerging therapies. Nat Rev Gastroenterol Hepatol. 2015, 12:446-57. 10.1038\/nrgastro.2015.111","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp031534","article-title":"Clinical practice. Acute infectious diarrhea","volume":"350","author":"Thielman NM","year":"2004","unstructured":"Thielman NM, Guerrant RL. Clinical practice. Acute infectious diarrhea. N Engl J Med. 2004, 350:38-47. 10.1056\/NEJMcp031534","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-1999-3","article-title":"Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors","volume":"31","author":"Gasparyan AY","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int. 2011, 31:1409-17. 10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1179\/2047480615Z.000000000329","article-title":"Writing narrative style literature reviews","volume":"24","author":"Ferrari R","year":"2015","unstructured":"Ferrari R. Writing narrative style literature reviews. Med Writing. 2015, 24:230-5. 10.1179\/2047480615Z.000000000329","journal-title":"Med Writing"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4300\/JGME-D-22-00480.1","article-title":"Narrative reviews: flexible, rigorous, and practical","volume":"14","author":"Sukhera J","year":"2022","unstructured":"Sukhera J. Narrative reviews: flexible, rigorous, and practical. J Grad Med Educ. 2022, 14:414-7. 10.4300\/JGME-D-22-00480.1","journal-title":"J Grad Med Educ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3747\/co.19.1054","article-title":"Supportive care treatments for toxicities of anti-egfr and other targeted agents","volume":"19","author":"Melosky B","year":"2012","unstructured":"Melosky B. Supportive care treatments for toxicities of anti-egfr and other targeted agents. Curr Oncol. 2012, 19:S59-63. 10.3747\/co.19.1054","journal-title":"Curr Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33100","article-title":"MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy","volume":"126","author":"Elad S","year":"2020","unstructured":"Elad S, Cheng KK, Lalla RV, et al.. MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020, 126:4423-31. 10.1002\/cncr.33100","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30109-2","article-title":"Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial","volume":"18","author":"Rugo HS","year":"2017","unstructured":"Rugo HS, Seneviratne L, Beck JT, et al.. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017, 18:654-62. 10.1016\/S1470-2045(17)30109-2","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila F","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, et al.. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016, 27:v119-33. 10.1093\/annonc\/mdw270","journal-title":"Ann Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO Guideline Update","volume":"38","author":"Hesketh PJ","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, et al.. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020, 38:2782-97. 10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro M","year":"2012","unstructured":"Aapro M, Molassiotis A, Dicato M, et al.. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012, 23:1986-92. 10.1093\/annonc\/mds021","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3324-x","article-title":"MASCC\/ESMO Antiemetic Guidelines: introduction to the 2016 guideline update","volume":"25","author":"Molassiotis A","year":"2017","unstructured":"Molassiotis A, Aapro M, Herrstedt J, Gralla R, Roila F. MASCC\/ESMO Antiemetic Guidelines: introduction to the 2016 guideline update. Support Care Cancer. 2017, 25:267-9. 10.1007\/s00520-016-3324-x","journal-title":"Support Care Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4464-y","article-title":"ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients","volume":"27","author":"Razvi Y","year":"2019","unstructured":"Razvi Y, Chan S, McFarlane T, et al.. ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 2019, 27:87-95. 10.1007\/s00520-018-4464-y","journal-title":"Support Care Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00551-3","article-title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Chan A","year":"2016","unstructured":"Chan A, Delaloge S, Holmes FA, et al.. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016, 17:367-77. 10.1016\/S1470-2045(15)00551-3","journal-title":"Lancet Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.012","article-title":"Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial","volume":"31","author":"Barcenas CH","year":"2020","unstructured":"Barcenas CH, Hurvitz SA, Di Palma JA, et al.. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol. 2020, 31:1223-30. 10.1016\/j.annonc.2020.05.012","journal-title":"Ann Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.12.003","article-title":"Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer","volume":"67","author":"Chan A","year":"2023","unstructured":"Chan A, Ruiz-Borrego M, Marx G, et al.. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Breast. 2023, 67:94-101. 10.1016\/j.breast.2022.12.003","journal-title":"Breast"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2023.06.014","article-title":"Crofelemer for the management of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer","volume":"23","author":"Jacob S","year":"2023","unstructured":"Jacob S, Johnson M, Roque B, Quintal L, Rugo HS, Melisko M, Chien AJ. Crofelemer for the management of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Clin Breast Cancer. 2023, 23:721-8. 10.1016\/j.clbc.2023.06.014","journal-title":"Clin Breast Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00623-3","article-title":"HER2-positive breast cancer: is more treatment better?","volume":"17","author":"Rugo HS","year":"2016","unstructured":"Rugo HS, Chien AJ. HER2-positive breast cancer: is more treatment better?. Lancet Oncol. 2016, 17:268-70. 10.1016\/s1470-2045(15)00623-3","journal-title":"Lancet Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13531","article-title":"Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo HS","year":"2021","unstructured":"Rugo HS, Huober J, Garc\u00eda-S\u00e1enz JA, et al.. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021, 26:e53-65. 10.1002\/onco.13531","journal-title":"Oncologist"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9 F","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, et al.. Alpelisib for PIK3CA-mutated hormone receptor-positive advanced breast cancer. N Engl J Med. 2019, 380:1929-40. 10.1056\/NEJMoa1813904","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9 SE","year":"2015","unstructured":"Coutr\u00e9 SE, Barrientos JC, Brown JR, et al.. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015, 56:2779-86. 10.3109\/10428194.2015.1022770","journal-title":"Leuk Lymphoma"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani S","year":"2009","unstructured":"Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009, 10:559-68. 10.1016\/S1470-2045(09)70112-3","journal-title":"Lancet Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70142-1","article-title":"Bevacizumab-associated gastrointestinal perforation","volume":"10","author":"Chau I","year":"2009","unstructured":"Chau I, Cunningham D. Bevacizumab-associated gastrointestinal perforation. Lancet Oncol. 2009, 10:534-6. 10.1016\/S1470-2045(09)70142-1","journal-title":"Lancet Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.05.004","article-title":"Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma","volume":"77","author":"Rimassa L","year":"2019","unstructured":"Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev. 2019, 77:20-8. 10.1016\/j.ctrv.2019.05.004","journal-title":"Cancer Treat Rev"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2024.04.003","article-title":"Gastrointestinal toxicity of antibody drug conjugates (ADCs) in metastatic breast cancer: a pooled analysis","volume":"24","author":"Pedersini R","year":"2024","unstructured":"Pedersini R, Buffoni M, Petrelli F, et al.. Gastrointestinal toxicity of antibody drug conjugates (ADCs) in metastatic breast cancer: a pooled analysis. Clin Breast Cancer. 2024, 24:411-20. 10.1016\/j.clbc.2024.04.003","journal-title":"Clin Breast Cancer"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03748.x","article-title":"Erlotinib and pantoprazole: a relevant interaction or not?","volume":"70","author":"Ter Heine R","year":"2010","unstructured":"Ter Heine R, Fanggiday JC, Lankheet NA, Beijnen JH, Van Der Westerlaken MM, Staaks GH, Malingr\u00e9 MM. Erlotinib and pantoprazole: a relevant interaction or not?. Br J Clin Pharmacol. 2010, 70:908-11. 10.1111\/j.1365-2125.2010.03748.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2014.07.005","article-title":"Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer","volume":"16","author":"Chu MP","year":"2015","unstructured":"Chu MP, Ghosh S, Chambers CR, et al.. Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Cancer. 2015, 16:33-9. 10.1016\/j.cllc.2014.07.005","journal-title":"Clin Lung Cancer"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.2560","article-title":"Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer","volume":"34","author":"van Leeuwen RW","year":"2016","unstructured":"van Leeuwen RW, Peric R, Hussaarts KG, et al.. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2016, 34:1309-14. 10.1200\/JCO.2015.65.2560","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000552","article-title":"Effects of proton pump inhibitor coadministration on the plasma concentration of erlotinib in patients with non-small cell lung cancer","volume":"40","author":"Ohgami M","year":"2018","unstructured":"Ohgami M, Kaburagi T, Kurosawa A, Doki K, Shiozawa T, Hizawa N, Homma M. Effects of proton pump inhibitor coadministration on the plasma concentration of erlotinib in patients with non-small cell lung cancer. Ther Drug Monit. 2018, 40:699-704. 10.1097\/FTD.0000000000000552","journal-title":"Ther Drug Monit"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.164","article-title":"Erlotinib and gastric acid-reducing agents: a combination to avoid or to support?","volume":"96","author":"Oude Munnink TH","year":"2014","unstructured":"Oude Munnink TH, Schouwink JH, Colen HB, Movig KL. Erlotinib and gastric acid-reducing agents: a combination to avoid or to support?. Clin Pharmacol Ther. 2014, 96:658. 10.1038\/clpt.2014.164","journal-title":"Clin Pharmacol Ther"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw530","article-title":"Erlotinib and acid suppressive agents: is it worth to take a coke?","volume":"28","author":"Retamero A","year":"2017","unstructured":"Retamero A, Conde-Est\u00e9vez D. Erlotinib and acid suppressive agents: is it worth to take a coke?. Ann Oncol. 2017, 28:192-3. 10.1093\/annonc\/mdw530","journal-title":"Ann Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2019.01.029","article-title":"Drug interactions of cola-containing drinks","volume":"38","author":"Nomani H","year":"2019","unstructured":"Nomani H, Moghadam AT, Emami SA, Mohammadpour AH, Johnston TP, Sahebkar A. Drug interactions of cola-containing drinks. Clin Nutr. 2019, 38:2545-51. 10.1016\/j.clnu.2019.01.029","journal-title":"Clin Nutr"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan M","year":"2021","unstructured":"Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology. 2021, 160:1384-93. 10.1053\/j.gastro.2020.08.063","journal-title":"Gastroenterology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR -mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria JC","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al.. Osimertinib in untreated EGFR -mutated advanced non-small-cell lung cancer. N Engl J Med. 2018, 378:113-25. 10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR -mutated advanced NSCLC","volume":"382","author":"Ramalingam SS","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, et al.. Overall survival with osimertinib in untreated, EGFR -mutated advanced NSCLC. N Engl J Med. 2020, 382:41-50. 10.1056\/NEJMoa1913662","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu YL","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, et al.. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017, 18:1454-66. 10.1016\/S1470-2045(17)30608-3","journal-title":"Lancet Oncol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30778-8","article-title":"Overall survival with osimertinib in untreated NSCLC","volume":"21","author":"Gourd E","year":"2020","unstructured":"Gourd E. Overall survival with osimertinib in untreated NSCLC. Lancet Oncol. 2020, 21:15. 10.1016\/S1470-2045(19)30778-8","journal-title":"Lancet Oncol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30684-8","article-title":"Treatment choice in EGFR-mutant non-small-cell lung cancer","volume":"18","author":"Brueckl WM","year":"2017","unstructured":"Brueckl WM. Treatment choice in EGFR-mutant non-small-cell lung cancer. Lancet Oncol. 2017, 18:1425-6. 10.1016\/S1470-2045(17)30684-8","journal-title":"Lancet Oncol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30923-3","article-title":"Dacomitinib in NSCLC: a positive trial with little clinical impact","volume":"19","author":"Addeo A","year":"2018","unstructured":"Addeo A. Dacomitinib in NSCLC: a positive trial with little clinical impact. Lancet Oncol. 2018, 19:4. 10.1016\/S1470-2045(17)30923-3","journal-title":"Lancet Oncol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0346-6","article-title":"Upfront osimertinib - winner takes it all?","volume":"17","author":"Remon J","year":"2020","unstructured":"Remon J, Lopes G. Upfront osimertinib - winner takes it all?. Nat Rev Clin Oncol. 2020, 17:202-3. 10.1038\/s41571-020-0346-6","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/465868-gastrointestinal-toxicities-of-targeted-cancer-therapies-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T16:00:28Z","timestamp":1774454428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/465868-gastrointestinal-toxicities-of-targeted-cancer-therapies-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":49,"URL":"https:\/\/doi.org\/10.7759\/cureus.105842","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,25]]}}}